Application of fullerenes in nanomedicine: an update

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Rao CNR, Cheetham AK. Science and technology of nanomaterials: current status and future prospects. J. Mater. Chem.11(12),2887–2894 (2001).
  CASGoogle Scholar
• 2  Liu Z, Robinson JT, Tabakman SM, Yang K, Dai HJ. Carbon materials for drug delivery and cancer therapy. Mater. Today14(7–8),316–323 (2011).
  CASGoogle Scholar
• 3  Lu FS, Gu LR, Meziani MJ et al. Advances in bioapplications of carbon nanotubes. Adv. Mater.21(2),139–152 (2009).
  CASGoogle Scholar
• 4  Sun Z, Liu Z, Meng J et al. Carbon nanotubes enhance cytotoxicity mediated by human lymphocytes in vitro. PloS One6(6),e21073 (2011).
  Medline CASGoogle Scholar
• 5  Shen H, Zhang LM, Liu M, Zhang ZJ. Biomedical applications of graphene. Theranostics2(3),283–294 (2012).
  Medline CASGoogle Scholar
• 6  Feng LZ, Zhang SA, Liu ZA. Graphene based gene transfection. Nanoscale3(3),1252–1257 (2011).
  Medline CASGoogle Scholar
• 7  Basso AS, Frenkel D, Quintana FJ et al. Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. J. Clin. Invest.118(4),1532–1543 (2008).
  Medline CASGoogle Scholar
• 8  Dugan LL, Turetsky DM, Du C et al. Carboxyfullerenes as neuroprotective agents. Proc. Natl Acad. Sci. USA94(17),9434–9439 (1997).
  Medline CASGoogle Scholar
• 9  Bosi S, Da RT, Spalluto G, Balzarini J, Prato M. Synthesis and anti-HIV properties of new water-soluble bis-functionalized[60]fullerene derivatives. Bioorg. Med. Chem. Lett.13(24),4437–4440 (2003).
  Medline CASGoogle Scholar
• 10  Marchesan S, Da RT, Spalluto G, Balzarini J, Prato M. Anti-HIV properties of cationic fullerene derivatives. Bioorg. Med. Chem. Lett.15(15),3615–3618 (2005).
  Medline CASGoogle Scholar
• 11  Berger CS, Marks JW, Bolskar RD, Rosenblum MG, Wilson LJ. Cell internalization studies of gadofullerene-(ZME-018) immunoconjugates into A375m melanoma cells. Transl. Oncol.4(6),350–354 (2011).
  MedlineGoogle Scholar
• 12  Daroczi B, Kari G, McAleer MF, Wolf JC, Rodeck U, Dicker AP. In vivo radioprotection by the fullerene nanoparticle DF-1 as assessed in a zebrafish model. Clin. Cancer Res.12(23),7086–7091 (2006).
  Medline CASGoogle Scholar
• 13  Lai YL, Murugan P, Hwang KC. Fullerene derivative attenuates ischemia-reperfusion-induced lung injury. Life Sci.72(11),1271–1278 (2003).
  Medline CASGoogle Scholar
• 14  Gonzalez KA, Wilson LJ, Wu W, Nancollas GH. Synthesis and in vitro characterization of a tissue-selective fullerene: vectoring C(60)(OH)(16)AMBP to mineralized bone. Bioorg. Med. Chem.10(6),1991–1997 (2002).
  Medline CASGoogle Scholar
• 15  Dellinger A, Zhou Z, Lenk R, Macfarland D, Kepley CL. Fullerene nanomaterials inhibit phorbol myristate acetate-induced inflammation. Exp. Dermatol.18(12),1079–1081 (2009).
  Medline CASGoogle Scholar
• 16  Tsao N, Luh TY, Chou CK et al.In vitro action of carboxyfullerene. J. Antimicrob. Chemother.49(4),641–649 (2002).
  Medline CASGoogle Scholar
• 17  Quick KL, Ali SS, Arch R, Xiong C, Wozniak D, Dugan LL. A carboxyfullerene SOD mimetic improves cognition and extends the lifespan of mice. Neurobiol. Aging29(1),117–128 (2008).▪▪ Fullerenes used as the first demonstration of administered antioxidants with mitochondrial activity and nervous system penetration not only increased lifespan, but also rescued age-related cognitive impairment in mammals.
  Medline CASGoogle Scholar
• 18  Baati T, Bourasset F, Gharbi N et al. The prolongation of the lifespan of rats by repeated oral administration of [60]fullerene. Biomaterials33(19),4936–4946 (2012).▪ Revealed that aqueous fullerene suspensions not only failed to produce acute or subacute toxicity in rodents, but could also protect their livers in a dose-dependent manner against free radical damage and prolong the lifespan of rats by nearly 100% without showing toxic effects.
  Medline CASGoogle Scholar
• 19  Yamago S, Tokuyama H, Nakamura E et al.In vivo biological behavior of a water-miscible fullerene: ¹⁴C labeling, absorption, distribution, excretion and acute toxicity. Chem. Biol.2(6),385–389 (1995).
  Medline CASGoogle Scholar
• 20  Ryan JJ, Bateman HR, Stover A et al. Fullerene nanomaterials inhibit the allergic response. J. Immunol.179(1),665–672 (2007).▪▪ Identifies a new biological function for fullerenes and may represent a novel way to control mast cell-dependent diseases, including asthma, inflammatory arthritis, heart disease and multiple sclerosis.
  Medline CASGoogle Scholar
• 21  Dellinger A, Zhou Z, Norton SK, Lenk R, Conrad D, Kepley CL. Uptake and distribution of fullerenes in human mast cells. Nanomedicine6(4),575–582 (2010).
  Medline CASGoogle Scholar
• 22  Norton SK, Dellinger A, Zhou Z et al. A new class of human mast cell and peripheral blood basophil stabilizers that differentially control allergic mediator release. Clin. Transl. Sci.3(4),158–169 (2010).
  Medline CASGoogle Scholar
• 23  Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature454(7203),445–454 (2008).
  Medline CASGoogle Scholar
• 24  Kobayashi T, Miura T, Haba T et al. An essential role of mast cells in the development of airway hyperresponsiveness in a murine asthma model. J. Immunol.164(7),3855–3861 (2000).
  Medline CASGoogle Scholar
• 25  Williams CM, Galli SJ. Mast cells can amplify airway reactivity and features of chronic inflammation in an asthma model in mice. J. Exp. Med.192(3),455–462 (2000).
  Medline CASGoogle Scholar
• 26  Gordon JR, Galli SJ. Mast cells as a source of both preformed and immunologically inducible TNF-alpha/cachectin. Nature346,274–276 (1990).
  Medline CASGoogle Scholar
• 27  Brightling C, Berry M, Amrani Y. Targeting TNF-alpha: a novel therapeutic approach for asthma. J. Allergy Clin. Immunol.121(1),5–10 (2008).
  Medline CASGoogle Scholar
• 28  Kepley CL, Mcfeeley PJ, Oliver JM, Lipscomb MF. Immunohistochemical detection of human basophils in postmortem cases of fatal asthma. Am. J. Respir. Crit. Care Med.164(6),1053–1058 (2001).
  Medline CASGoogle Scholar
• 29  Kepley CL, Craig SS, Schwartz LB. Identification and partial characterization of a unique marker for human basophils. J. Immunol.154(12),6548–6555 (1995).
  Medline CASGoogle Scholar
• 30  Schroeder JT. Basophils beyond effector cells of allergic inflammation. Adv. Immunol.101,123–161 (2009).
  Medline CASGoogle Scholar
• 31  Jackson DJ, Sykes A, Mallia P, Johnston SL. Asthma exacerbations: origin, effect, and prevention. J. Allergy Clin. Immunol.128(6),1165–1174 (2011).
  MedlineGoogle Scholar
• 32  Norton SK, Wijesinghe DS, Dellinger A et al. Epoxyeicosatrienoic acids are involved in the C(70) fullerene derivative-induced control of allergic asthma. J. Allergy Clin. Immunol.130(3),761–769 (2012).▪▪ Fullerene-treated mice were found to have significantly reduced airway inflammation, eosinophilia and bronchoconstriction associated with allergic asthma.
  Medline CASGoogle Scholar
• 33  Sudhahar V, Shaw S, Imig JD. Epoxyeicosatrienoic acid analogs and vascular function. Curr. Med. Chem.17(12),1181–1190 (2010).
  Medline CASGoogle Scholar
• 34  Pfister SL, Gauthier KM, Campbell WB. Vascular pharmacology of epoxyeicosatrienoic acids. Adv. Pharmacol.60,27–59 (2010).
  Medline CASGoogle Scholar
• 35  Morin C, Rousseau E. Effects of 5-oxo-ETE and 14,15-EET on reactivity and Ca²⁺ sensitivity in guinea pig bronchi. Prostaglandins Other Lipid Mediat.82(1–4),30–41 (2007).
  Medline CASGoogle Scholar
• 36  Morin C, Sirois M, Echave V, Gomes MM, Rousseau E. EET displays anti-inflammatory effects in TNF-alpha stimulated human bronchi: putative role of CPI-17. Am. J. Respir. Cell Mol. Biol.38(2),192–201 (2008).
  Medline CASGoogle Scholar
• 37  Node K, Huo Y, Ruan X et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science285(5431),1276–1279 (1999).
  Medline CASGoogle Scholar
• 38  Nigrovic PA, Lee DM. Synovial mast cells: role in acute and chronic arthritis. Immunol. Rev.217,19–37 (2007).
  Medline CASGoogle Scholar
• 39  Woolley DE. The mast cell in inflammatory arthritis. N. Engl. J. Med.348(17),1709–1711 (2003).
  Medline CASGoogle Scholar
• 40  Irani AA, Golzar N, Deblois G, Gruber B, Schwartz LB. Distribution of mast cell subsets in rheumatoid arthritis and osteoarthritis synovia. Arthritis Rheum.30,66 (1987).
  Google Scholar
• 41  Bridges AJ, Malone DG, Jicinsky J et al. Human synovial mast cell involvement in rheumatoid arthritis and osteoarthritis: relationship to disease type, clinical activity, and antirheumatic therapy. Arthritis Rheum.34,1116–1124 (1991).
  Medline CASGoogle Scholar
• 42  Gotis-Graham I, Smith MD, Parker A, Mcneil HP. Synovial mast cell responses during clinical improvement in early rheumatoid arthritis. Ann. Rheum. Dis.57(11),664–671 (1998).
  Medline CASGoogle Scholar
• 43  Lavery JP, Lisse JR. Preliminary study of the tryptase levels in the synovial fluid of patients with inflammatory arthritis. Ann. Allergy72,425–427 (1994).
  Medline CASGoogle Scholar
• 44  Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science.297(5587),1689–1692 (2002).
  Medline CASGoogle Scholar
• 45  Dinser R. Animal models for arthritis. Best Pract. Res. Clin. Rheumatol.22(2),253–267 (2008).
  Medline CASGoogle Scholar
• 46  Nigrovic PA, Lee DM. Mast cells in autoantibody responses and arthritis. Novartis Found. Symp.271,200–209 (2005).
  Medline CASGoogle Scholar
• 47  Winyard PG, Ryan B, Eggleton P et al. Measurement and meaning of markers of reactive species of oxygen, nitrogen and sulfur in healthy human subjects and patients with inflammatory joint disease. Biochem. Soc. Trans.39,1226–1232 (2011).
  Medline CASGoogle Scholar
• 48  Zhou Z, Lenk RP, Dellinger A, Wilson SR, Sadler R, Kepley CL. Liposomal formulation of amphiphilic fullerene antioxidants. Bioconjug. Chem.21(9),1656–1661 (2010).
  Medline CASGoogle Scholar
• 49  Ehrich M, van Tassell R, Li Y, Zhou Z, Kepley CL. Fullerene antioxidants decrease organophosphate-induced acetylcholinesterase inhibition in vitro. Toxicol. In Vitro25(1),301–307 (2011).
  Medline CASGoogle Scholar
• 50  Zhao W, Gomez G, Macey M, Kepley CL, Schwartz LB. In vitro desensitization of human skin mast cells. J. Clin. Immunol.32(1),150–160 (2011).
  MedlineGoogle Scholar
• 51  Chirico F, Fumelli C, Marconi A et al. Carboxyfullerenes localize within mitochondria and prevent the UVB-induced intrinsic apoptotic pathway. Exp. Dermatol.16(5),429–436 (2007).
  Medline CASGoogle Scholar
• 52  Fumelli C, Marconi A, Salvioli S et al. Carboxyfullerenes protect human keratinocytes from ultraviolet-B-induced apoptosis. J. Invest. Dermatol.115(5),835–841 (2000).
  Medline CASGoogle Scholar
• 53  Pitman N, Asquith DL, Murphy G, Liew FY, Mcinnes IB. Collagen-induced arthritis is not impaired in mast cell-deficient mice. Ann. Rheum. Dis.70(6),1170–1171 (2011).
  MedlineGoogle Scholar
• 54  Brown MA, Tanzola MB, Robbie-Ryan M. Mechanisms underlying mast cell influence on EAE disease course. Mol. Immunol.38(16–18),1373–1378 (2002).
  Medline CASGoogle Scholar
• 55  Gregory GD, Bickford A, Robbie-Ryan M, Tanzola M, Brown MA. MASTering the immune response: mast cells in autoimmunity. Novartis Found. Symp.271,215–225; discussion 225–231 (2005).
  Medline CASGoogle Scholar
• 56  Secor VH, Secor WE, Gutekunst CA, Brown MA. Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis. J. Exp. Med.191(5),813–822 (2000).
  Medline CASGoogle Scholar
• 57  Li LB, Reith ME. Modeling of the interaction of Na⁺ and K⁺ with the binding of dopamine and [³H]WIN 35,428 to the human dopamine transporter. J. Neurochem.72(3),1095–1109 (1999).
  Medline CASGoogle Scholar
• 58  Dugan LL, Gabrielsen JK, Yu SP, Lin TS, Choi DW. Buckminsterfullerenol free radical scavengers reduce excitotoxic and apoptotic death of cultured cortical neurons. Neurobiol. Dis.3(2),129–135 (1996).
  Medline CASGoogle Scholar
• 59  Ali SS, Hardt JI, Quick KL et al. A biologically effective fullerene (C₆₀) derivative with superoxide dismutase mimetic properties. Free Radic. Biol. Med.37(8),1191–1202 (2004).
  Medline CASGoogle Scholar
• 60  Borland MK, Trimmer PA, Rubinstein JD et al. Chronic, low-dose rotenone reproduces Lewy neurites found in early stages of Parkinson’s disease, reduces mitochondrial movement and slowly kills differentiated SH-SY5Y neural cells. Mol. Neurodegener.3,21 (2008).
  MedlineGoogle Scholar
• 61  Gilgun-Sherki Y, Melamed E, Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J. Neurol.251(3),261–268 (2004).
  Medline CASGoogle Scholar
• 62  Bakry R, Vallant RM, Najam-Ul-Haq M et al. Medicinal applications of fullerenes. Int. J. Nanomedicine2(4),639–649 (2007).
  Medline CASGoogle Scholar
• 63  Mody VV, Nounou MI, Bikram M. Novel nanomedicine-based MRI contrast agents for gynecological malignancies. Adv. Drug Deliv. Rev.61(10),795–807 (2009).
  Medline CASGoogle Scholar
• 64  Nitta N, Seko A, Sonoda A et al. Is the use of fullerene in photodynamic therapy effective for atherosclerosis? Cardiovasc. Intervent. Radiol.31(2),359–366 (2008).
  MedlineGoogle Scholar
• 65  Bolskar RD. Gadofullerene MRI contrast agents. Nanomedicine (Lond.)3(2),201–213 (2008).
  CASGoogle Scholar
• 66  Chewning RH, Murphy KJ. Gadolinium-based contrast media and the development of nephrogenic systemic fibrosis in patients with renal insufficiency. J. Vasc. Interv. Radiol.18(3),331–333 (2007).
  MedlineGoogle Scholar
• 67  Runge VM. Gadolinium and nephrogenic systemic fibrosis. AJR Am. J. Roentgenol.192(4),W195–W196 (2009).
  MedlineGoogle Scholar
• 68  Ledneva E, Karie S, Launay-Vacher V, Janus N, Deray G. Renal safety of gadolinium-based contrast media in patients with chronic renal insufficiency. Radiology250(3),618–628 (2009).
  MedlineGoogle Scholar
• 69  Cowper SE. Nephrogenic systemic fibrosis: a review and exploration of the role of gadolinium. Adv. Dermatol.23,131–154 (2007).
  MedlineGoogle Scholar
• 70  Macfarland DK, Walker KL, Lenk RP et al. Hydrochalarones: a novel endohedral metallofullerene platform for enhancing magnetic resonance imaging contrast. J. Med. Chem.51(13),3681–3683 (2008).
  Medline CASGoogle Scholar
• 71  Ouimet T, Lancelot E, Hyafil F et al. Molecular and cellular targets of the MRI contrast agent p947 for atherosclerosis imaging. Mol. Pharm.9(4),850–861 (2012).
  Medline CASGoogle Scholar
• 72  Uno K, Nicholls SJ. Biomarkers of inflammation and oxidative stress in atherosclerosis. Biomark. Med.4(3),361–373 (2010).
  CASGoogle Scholar
• 73  Sadeghi MM, Glover DK, Lanza GM, Fayad ZA, Johnson LL. Imaging atherosclerosis and vulnerable plaque. J. Nucl. Med.51(Suppl. 1),51S–65S (2010).
  MedlineGoogle Scholar
• 74  Nergiz-Unal R, Rademakers T, Cosemans JM, Heemskerk JW. CD36 as a multiple-ligand signaling receptor in atherothrombosis. Cardiovasc. Hematol. Agents Med. Chem.9(1),42–55 (2011).
  Medline CASGoogle Scholar
• 75  Collot-Teixeira S, Martin J, Rmott-Roe C, Poston R, Mcgregor JL. CD36 and macrophages in atherosclerosis. Cardiovasc. Res.75(3),468–477 (2007).
  Medline CASGoogle Scholar
• 76  Ge Y, Elghetany MT. CD36: a multiligand molecule. Lab. Hematol.11(1),31–37 (2005).
  Medline CASGoogle Scholar
• 77  Silverstein RL, Febbraio M. CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci. Signal.2(72),re3 (2009).
  MedlineGoogle Scholar
• 78  Podrez EA, Poliakov E, Shen Z et al. Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36. J. Biol. Chem.277(41),38503–38516 (2002).
  Medline CASGoogle Scholar
• 79  Kolovou G, Anagnostopoulou K, Mikhailidis DP, Cokkinos DV. Apolipoprotein E knockout models. Curr. Pharm. Des.14(4),338–351 (2008).
  Medline CASGoogle Scholar
• 80  Patra CR, Jing Y, Xu YH et al. A core–shell nanomaterial with endogenous therapeutic and diagnostic functions. Cancer Nanotechnol.1(1),13–18 (2010).
  Medline CASGoogle Scholar
• 81  Yigit MV, Zhu L, Ifediba MA et al. Noninvasive MRI-SERS imaging in living mice using an innately bimodal nanomaterial. ACS Nano5(2),1056–1066 (2011).
  Medline CASGoogle Scholar
• 82  Park JH, von Maltzahn G, Ruoslahti E, Bhatia SN, Sailor MJ. Micellar hybrid nanoparticles for simultaneous magnetofluorescent imaging and drug delivery. Angew. Chem. Int. Ed. Engl.47(38),7284–7288 (2008).
  Medline CASGoogle Scholar
• 83  Park JH, Von Maltzahn G, Zhang L et al. Magnetic iron oxide nanoworms for tumor targeting and imaging. Adv. Mater.20(9),1630–1635 (2008).
  Medline CASGoogle Scholar
• 84  Von Maltzahn G, Ren Y, Park JH et al.In vivo tumor cell targeting with “click” nanoparticles. Bioconjug. Chem.19(8),1570–1578 (2008).
  Medline CASGoogle Scholar
• 85  Jaffer FA, Libby P, Weissleder R. Molecular and cellular imaging of atherosclerosis: emerging applications. J. Am. Coll. Cardiol.47(7),1328–1338 (2006).
  Medline CASGoogle Scholar
• 86  Jaffer FA, Nahrendorf M, Sosnovik D, Kelly KA, Aikawa E, Weissleder R. Cellular imaging of inflammation in atherosclerosis using magnetofluorescent nanomaterials. Mol. Imaging5(2),85–92 (2006).
  MedlineGoogle Scholar
• 87  Mccarthy JR, Jaffer FA, Weissleder R. A macrophage-targeted theranostic nanoparticle for biomedical applications. Small2(8–9),983–987 (2006).
  Medline CASGoogle Scholar
• 88  Li C, Hall WA, Jin N, Todhunter DA, Panoskaltsis-Mortari A, Vallera DA. Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice. Protein Eng.15(5),419–427 (2002).
  MedlineGoogle Scholar
• 89  Todhunter DA, Hall WA, Rustamzadeh E, Shu Y, Doumbia SO, Vallera DA. A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model. Protein Eng. Des. Sel.17(2),157–164 (2004).
  Medline CASGoogle Scholar
• 90  Madhankumar AB, Slagle-Webb B, Mintz A, Sheehan JM, Connor JR. Interleukin13 receptor-targeted nanovesicles are a potential therapy for glioblastoma multiforme. Mol. Cancer Ther.5(12),3162–3169 (2006).
  Medline CASGoogle Scholar
• 91  Oberdorster E. Manufactured nanomaterials (fullerenes, C₆₀) induce oxidative stress in the brain of juvenile largemouth bass. Environ. Health Perspect.112(10),1058–1062 (2004).
  Medline CASGoogle Scholar
• 92  Barnaby JF. Study raises concerns about carbon particles. New York Times, 29th March (2004).
  Google Scholar
• 93  Zhu S, Oberdorster E, Haasch ML. Toxicity of an engineered nanoparticle (fullerene, C₆₀) in two aquatic species, Daphnia and fathead minnow. Mar. Environ. Res.62(Suppl.),S5–S9 (2006).
  Medline CASGoogle Scholar
• 94  Henry TB, Petersen EJ, Compton RN. Aqueous fullerene aggregates (nC₆₀) generate minimal reactive oxygen species and are of low toxicity in fish: a revision of previous reports. Curr. Opin. Biotechnol.22(4),533–537 (2011).
  Medline CASGoogle Scholar
• 95  Chen HH, Yu C, Ueng TH et al. Acute and subacute toxicity study of water-soluble polyalkylsulfonated C₆₀ in rats. Toxicol. Pathol.26(1),143–151 (1998).
  Medline CASGoogle Scholar
• 96  Mori T, Takada H, Ito S, Matsubayashi K, Miwa N, Sawaguchi T. Preclinical studies on safety of fullerene upon acute oral administration and evaluation for no mutagenesis. Toxicology225(1),48–54 (2006).
  Medline CASGoogle Scholar
• 97  Gharbi N, Pressac M, Hadchouel M, Szwarc H, Wilson SR, Moussa F. [60]fullerene is a powerful antioxidant in vivo with no acute or subacute toxicity. Nano. Lett.5(12),2578–2585 (2005).
  Medline CASGoogle Scholar
• 98  Ibrahim M, Saleh NA, Elshemey WM, Elsayed AA. Fullerene derivative as anti-HIV protease inhibitor: molecular modeling and QSAR approaches. Mini. Rev. Med. Chem.12(6),447–451 (2012).
  Medline CASGoogle Scholar
• 99  Luo Z, Xu X, Zhang X, Hu L. Development of calixarenes, cyclodextrins and fullerenes as new platforms for anti-HIV drug design: an overview. Mini Rev. Med. Chem.13(8),1160–1165 (2013).
  Medline CASGoogle Scholar
• 100  Kornev AB, Peregudov AS, Martynenko VM, Balzarini J, Hoorelbeke B, Troshin PA. Synthesis and antiviral activity of highly water-soluble polycarboxylic derivatives of [70]fullerene. Chem. Commun. (Camb.)47(29),8298–8300 (2011).
  Medline CASGoogle Scholar
• 101  Zhu ZW, Schuster DI, Tuckerman ME. Molecular dynamics study of the connection between flap closing and binding of fullerene-based inhibitors of the HIV-1 protease. Biochemistry42(5),1326–1333 (2003).
  Medline CASGoogle Scholar
• 102  Marcorin GL, Da Ros T, Castellano S et al. Design and synthesis of novel [60]fullerene derivatives as potential HIV aspartic protease inhibitors. Org. Lett.2(25),3955–3958 (2000).
  Medline CASGoogle Scholar
• 103  Rancan F, Rosan S, Boehm F et al. Cytotoxicity and photocytotoxicity of a dendritic C-60 mono-adduct and a malonic acid C-60 tris-adduct on Jurkat cells. J. Photoch. Photobio. B67(3),157–162 (2002).
  Medline CASGoogle Scholar
• 104  Liu Y, Wang H. Nanomedicine: nanotechnology tackles tumours. Nat. Nanotechnol.2(1),20–21 (2007).
  Medline CASGoogle Scholar
• 105  Saathoff JG, Inman AO, Xia XR, Riviere JE, Monteiro-Riviere NA. In vitro toxicity assessment of three hydroxylated fullerenes in human skin cells. Toxicol. In Vitro25(8),2105–2112 (2011).
  Medline CASGoogle Scholar
• 201  ClinicalTrials.gov.http://clinicaltrials.gov/
  Google Scholar
• 202  US FDA. Nanotechnology.http://www.fda.gov/ScienceResearch/SpecialTopics/Nanotechnology/
  Google Scholar
• 203  National Cancer Institute. Nanotechnology Characterization Laboratory Objectives.http://ncl.cancer.gov/objectives_ncl_obj1.asp
  Google Scholar